Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02030405 · ClinicalTrials.gov registry record · Phase 2
Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 2 study, sponsored by Steven E. Coutre.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT02030405: Clinical Trial Phase 2 study, sponsored by Steven E. Coutre.
NCT02030405 is a Phase 2 study that was terminated before completion, run by Steven E. Coutre. The registered enrollment target is 4 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02030405, a Phase 2 study, was terminated before completion, sponsored by Steven E. Coutre.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
This phase 2 trial studies how well ixazomib(MLN9708) works in treating study participants with relapsed or refractory acute myeloid leukemia. Ixazomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Primary Outcome
Overall response rate after 3 cycles of treatment (9 weeks) was assessed as complete remission (CR); CR with incomplete recovery (CRi); and partial remission (PR) with MLN9708, in participants with NPM1-mutated AML by LeukemiaNet1 guidelines: Although achievement of complete remission (CR) has unique clinical significance for improved overall survival (OS) and relapse-free survival (RFS) compared to achievement of CRi with incomplete platelet recovery, the latter is still a clinically meaningfu
Interventions
- DRUG Ixazomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2014-03 |
| Est. Completion | 2015-11 |
| Phase | Phase 2 |
Why NCT02030405 stopped before completion
NCT02030405 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Ixazomib is the first listed.
NCT02030405 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02030405 about?
NCT02030405 is a clinical study titled "Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia". This phase 2 trial studies how well ixazomib(MLN9708) works in treating study participants with relapsed or refractory acute myeloid leukemia. Ixazomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT02030405?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2014-03. Estimated completion is 2015-11.
What interventions are being tested in trial NCT02030405?
The interventions under investigation include: Ixazomib (DRUG).
Who is sponsoring clinical trial NCT02030405?
This trial is sponsored by Steven E. Coutre, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02030405's enrollment target sits among peer trials
4 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia